The Quantellect read.As of Nov 19, 2026, 5 active firms cover Biodesix Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $32.00 to $40.00, so the covering firms are broadly aligned. The average target of $36.25 sits 330% above the current $8.43. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees revenue growth near 25% this year and 20% next, consensus EPS building from about $-0.69 next quarter toward $-1.96 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$36.25
+330.0% upside
Average target across 4 active firms as of Nov 19, 2026 vs $8.43 current
Highest Target$40.00
Average Target$36.25
Lowest Target$32.00
Detailed analyst forecasts for BDSX
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate BDSX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BDSX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.69
Range $-0.78 – $-0.53 · 6 analysts · -15% YoY
Next period, 6 analysts expect Biodesix Inc to earn $-0.69 a share (range $-0.78 – $-0.53), versus $-0.81 a year earlier. Full-year consensus is $-2.90, growing to $-1.96 the year after.
REVENUE · NEXT QUARTER
$28.6M
Range $26.1M – $31.3M · 6 analysts · +27% YoY
Revenue is expected to reach $28.6M (range $26.1M – $31.3M), +27.0% year-over-year. Full-year consensus is $104.7M, rising to $125.3M next year.
Top analysts covering Biodesix Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BDSX.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #186
Buy
$2.00-76.3% to target
Overall win rate
47%
+ Follow
#2
KM
Kyle Mikson
Canaccord Genuity · Rank #202
Buy
$35.00+315.2% to target
Overall win rate
40%
+ Follow
#3
TF
Thomas Flaten
Lake Street · Rank #306
Buy
$30.00+255.9% to target
Overall win rate
40%
+ Follow
#4
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$38.00+350.8% to target
Overall win rate
34%
+ Follow
#5
Daniel Brennan
TD Cowen
Buy
$30.00+255.9% to target
Coverage
—
+ Follow
BDSX stock forecast FAQ
What is BDSX's average 12-month price target?+
The 4 active firms with a live target average $36.25 for Biodesix Inc over the next 12 months, ranging from a $40.00 high to a $32.00 low, as of Nov 19, 2026.
Is BDSX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BDSX?+
The Street-high target is $40.00 (TD Cowen), and the Street-low is $32.00 (Roth Capital). The average of all 4 active-firm targets is $36.25.
How many active Wall Street firms cover BDSX?+
5 active firms have a recognized rating on Biodesix Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BDSX?+
Among analysts who currently cover BDSX, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #186). Their current call is Buy with a $2.00 target.
What is Biodesix Inc's projected EPS for next quarter?+
The consensus estimate is $-0.69 per share (range $-0.78 – $-0.53) across 6 analysts. Full-year EPS is projected at $-2.90, rising to $-1.96 the following year.
How much revenue is Biodesix Inc expected to report next quarter?+
Consensus revenue is $28.6M (range $26.1M – $31.3M). Full-year revenue is projected at $104.7M, growing to $125.3M next year.
Have analysts been upgrading or downgrading BDSX lately?+
As of Nov 19, 2026, 5 of 5 active firms rate BDSX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BDSX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.